Arcus Biosciences, INC

Arcus Biosciences stockholders re-elected four Class II directors and ratified the appointment of Ernst & Young LLP.

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 study for metastatic non-small cell lung cancer due to futility, and Gilead will not extend its option rights for early-stage pipeline programs.

Arcus Biosciences announced Chief Operating Officer Jennifer Jarrett's resignation, effective March 30, 2026, with her providing advisory services until June 30, 2026.

Arcus Biosciences reported its fourth-quarter and full-year 2025 financial results, highlighting strong casdatifan data and a cash runway extending into late 2028.

Arcus Biosciences amended its loan agreement, gaining access to an additional $150 million tied to clinical and regulatory milestones and extending the maturity date to 2030.

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies for advanced gastric and esophageal cancers due to futility.

Arcus Biosciences reported a net loss of $128 million for Q1 2026, an increase from the prior year, driven by lower collaboration revenues and continued investment in late-stage development.

Arcus Biosciences reported a significant increase in net loss for Q3 2025 despite advancing its late-stage clinical pipeline and securing new collaboration milestones.

Arcus Biosciences achieved net income in Q2 2025, driven by a one-time revenue adjustment, while advancing key oncology programs and securing a strong cash position.

Arcus Biosciences reports a net loss of $112 million for Q1 2025, while highlighting progress in its casdatifan program and a strategic shift away from a Phase 3 study for etrumadenant in third-line metastatic colorectal cancer.

Arcus Biosciences reports a net loss of $92 million for the third quarter of 2024, with total revenues reaching $48 million, primarily driven by collaboration agreements.

Arcus Biosciences reports a net loss of $97 million for the first half of 2024, while highlighting progress in clinical trials and strategic collaborations.

Arcus Biosciences reports increased net losses in 2025, discontinues a Phase 3 trial, but strengthens its financial position with new equity and debt financing.

Arcus Biosciences' 10-K filing summarizes the company's focus on developing cancer therapies, key collaborations, and financial results for the year ended December 31, 2024.

Arcus Biosciences has established a new severance benefits plan for eligible employees and filed its annual report on Form 10-K, detailing its financial performance and strategic initiatives.

Juan C. Jaen, President of Arcus Biosciences, Inc., sold 68,569 shares of common stock on July 9, 2026.

Arcus Biosciences President Juan C. Jaen reported the sale of company stock totaling over 31,000 shares across multiple transactions executed between June 22 and June 24, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences director Nicole Lambert was granted 5,700 restricted stock units and 16,900 stock options as part of annual compensation.

Director Patrick Machado acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

Director Yasunori Kaneko acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

General Counsel Carolyn C. Tang exercised 34,090 stock options in Arcus Biosciences, Inc. on June 11, 2026.

Arcus Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, with key proposals including director elections and executive compensation.

Arcus Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, with proxy materials available online.

Arcus Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.

Arcus Biosciences has scheduled its 2024 annual meeting of stockholders.

Arcus Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, and executive compensation.

Gilead Sciences, Inc. has filed an Amendment No. 6 to Schedule 13D, updating its beneficial ownership in Arcus Biosciences, Inc. to 25.6% of outstanding common stock.

Gilead Sciences, Inc.'s option to acquire additional shares in Arcus Biosciences, Inc., potentially increasing its stake to 35%, expired on July 13, 2025, leaving its beneficial ownership at 29.7%.

Gilead Sciences, Inc. has increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of stock purchases, including a recent public offering, reinforcing their strategic collaboration.

Gilead Sciences, Inc. has significantly increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of strategic share purchases and option exercises, reinforcing their ongoing collaboration.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Arcus Biosciences Inc. following an internal corporate realignment.

BlackRock, Inc. has reported an increased beneficial ownership of 10.4% in Arcus Biosciences Inc. common stock, holding 12,736,927 shares.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 4.1% beneficial ownership stake in Arcus Biosciences, Inc. as of September 30, 2025.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a passive beneficial ownership of 5.5% in Arcus Biosciences, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.4% passive beneficial ownership stake in Arcus Biosciences Inc. as of March 31, 2025.